Hepatitis B Virus News and Research

RSS

Viewpoints: Tea party missing the lesson; health care not an ordinary market; Va.'s Medicaid battle

But the Tea Party does have something to show for its five years of annoyance: Ted Cruz, senator from Texas. Cruz is probably best known for reading "Green Eggs and Ham" on the floor of the Senate during a 21-hour talkathon designed to ensure his place as the most hated man in that august chamber.

9 Jun 2014

New vaccine effective at preventing lung cancer in mice

Tweaking a protein expressed by most liver cancer cells has enabled scientists to make a vaccine that is exceedingly effective at preventing the disease in mice.

4 Jun 2014

Medicare to pay for hep C screenings for baby boomers

The decision comes amid controversy surrounding the costs of new drugs to treat the blood-borne virus. Meanwhile, two studies find that Medicare could save billions if doctors switched from an expensive eye medication to a similar, much cheaper one and, also, if Part D plans were selected based on the actual drugs patients take.

4 Jun 2014

HCV reactivation may not worsen survival outcomes for lymphoma patients with HIV

More than a quarter of HIV+ patients are also infected with the Hepatitis C virus (HCV), which may complicate treatment and care decisions after a cancer diagnosis. The specifics of those complications haven't been well-researched in the past. Results from a new Fox Chase Cancer Center study on this patient population may start filling in that gap.

31 May 2014

Biomedical scientists explore mechanisms of novel treatments for HCV

As new treatments for hepatitis C virus (HCV) are approved, biomedical scientists are exploring their mechanisms and what they reveal about the virus.

29 May 2014

Novel scrapbook-inspired test helps patients diagnosed with hepatitis C

To the relief of patients diagnosed with hepatitis C, the U.S. Food and Drug Administration approved two new treatments late last year, and a few more are on the way.

22 May 2014

DNA-directed RNA interference and hepatitis C: an interview with Carl Stubbings, Chief Business Officer, Benitec Biopharma

RNA interference (RNAi) is a naturally occurring process, which cells can use to silence, or ‘turn off’ unwanted genes.

From Quest Diagnostics 19 May 2014

Isis Pharmaceuticals receives $3 million milestone payment from GSK

Isis Pharmaceuticals, Inc. announced today that it has earned a $3.0 million milestone payment from GlaxoSmithKline (GSK) related to the initiation of a natural history study, which will support the advancement of one of the alliance programs.

15 May 2014

Scientists decrypt interaction network of hepatitis C virus proteins in living human cells

Scientists at the Helmholtz Zentrum München have for the first time decrypted the interaction network of hepatitis C virus proteins in living human cells. Their findings will contribute to a better understanding of the mechanisms behind inflammatory liver disease caused by hepatitis C viruses and open up new avenues for therapy development.

9 May 2014

AbbVie seeks marketing approval from EMA for all-oral, interferon-free therapy to treat HCV infection

AbbVie submitted marketing authorization applications (MAAs) to the European Medicines Agency seeking approval for the company’s investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection.

9 May 2014

Luminescent nanocrystals tags with high-speed scanning technology detects multiple viruses within minutes

A research team using tunable luminescent nanocrystals as tags to advance medical and security imaging have successfully applied them to high-speed scanning technology and detected multiple viruses within minutes.

9 May 2014

Isis Pharmaceuticals reports pro forma net operating loss of $22.6 million for Q1 2014

Isis Pharmaceuticals, Inc. today reported a pro forma net operating loss (NOL) of $22.6 million for the three months ended March 31, 2014 compared to pro forma operating income of $4.5 million for the same period in 2013.

6 May 2014

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

UCB announced today results from the PRECiSE 3 7-year open label extension clinical trial of Cimzia (certolizumab pegol), the longest continuous trial of an anti-TNF therapy evaluating long-term safety in Crohn's disease.

6 May 2014

Alcohol consumption linked with increased risk of advanced liver fibrosis in HIV patients

Consumption of alcohol has long been associated with an increased risk of advanced liver fibrosis, but a new study published online in Clinical Infectious Diseases from researchers at Penn Medicine and other institutions shows that association is drastically heightened in people co-infected with both HIV and chronic hepatitis C virus (HCV) infection.

5 May 2014

Study: New combination therapy to treat chronic hepatitis C

A new combination therapy allows chronic hepatitis C to be treated in a manner that is less aggressive yet equally efficient.

5 May 2014

Viewpoints: Boehner's 'truthful gaffe' on health law; Larry Kramer's AIDS crusade; costly drugs

Although "repeal and replace" has been the Republican position on Obamacare since 2010, "replace" has been there mainly because it polled well. Republicans were satisfied with the health-care status quo in 2009, and would have been glad to repeal Obamacare to return to it. As Steve Benen points out, Republicans voted for just-plain-repeal many times.

29 Apr 2014

Aetna raises earnings outlook

In other market news, coverage continues of the cost and effectiveness of Sovaldi, a new drug to treat hepatitis C, and the related earnings gained by Gilead Sciences, its manufacturer.

25 Apr 2014

Automated diagnostic technologies redefine infectious diseases

The diagnostics market for infectious diseases such as tuberculosis (TB), human immunodeficiency virus (HIV), hepatitis C virus and human papilloma virus is expanding, giving rise to commercial opportunities especially in the developing economies of Asia, Africa and Latin America.

22 Apr 2014

Genmab/GSK receive FDA sBLA approval for Arzerra in combination with chlorambucil for treatment of CLL

GlaxoSmithKline plc and Genmab A/S announced today that the U.S. Food and Drug Administration (FDA) has approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra® (ofatumumab), a CD20-directed cytolytic monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukaemia (CLL) for whom fludarabine-based therapy is considered inappropriate.

21 Apr 2014

Researchers identify mechanism that explains reason for persistence of hepatitis C virus

Researchers at the University of California, San Diego School of Medicine have identified a mechanism that explains why people with the hepatitis C virus get liver disease and why the virus is able to persist in the body for so long.

16 Apr 2014

Hepatitis B Virus News and Research

Viewpoints: Tea party missing the lesson; health care not an ordinary market; Va.'s Medicaid battle

New vaccine effective at preventing lung cancer in mice

Medicare to pay for hep C screenings for baby boomers

HCV reactivation may not worsen survival outcomes for lymphoma patients with HIV

Biomedical scientists explore mechanisms of novel treatments for HCV

Novel scrapbook-inspired test helps patients diagnosed with hepatitis C

DNA-directed RNA interference and hepatitis C: an interview with Carl Stubbings, Chief Business Officer, Benitec Biopharma

Isis Pharmaceuticals receives $3 million milestone payment from GSK

Scientists decrypt interaction network of hepatitis C virus proteins in living human cells

AbbVie seeks marketing approval from EMA for all-oral, interferon-free therapy to treat HCV infection

Luminescent nanocrystals tags with high-speed scanning technology detects multiple viruses within minutes

Isis Pharmaceuticals reports pro forma net operating loss of $22.6 million for Q1 2014

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

Alcohol consumption linked with increased risk of advanced liver fibrosis in HIV patients

Study: New combination therapy to treat chronic hepatitis C

Viewpoints: Boehner's 'truthful gaffe' on health law; Larry Kramer's AIDS crusade; costly drugs

Aetna raises earnings outlook

Automated diagnostic technologies redefine infectious diseases

Genmab/GSK receive FDA sBLA approval for Arzerra in combination with chlorambucil for treatment of CLL

Researchers identify mechanism that explains reason for persistence of hepatitis C virus

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News